1. Report Overview
1.1 Global Translational Regenerative Medicine Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Translational Regenerative Medicine Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8. Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Translational Regenerative Medicine
2.1 What is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine - From Bench to Bedside
2.2 Translational Regenerative Medicine - Market Breakdown
2.2.1 Stem Cell Therapy - Marketable Differentiation and Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered the Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering - In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins - Scaffold-Based Delivery of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report
3. Translational Regenerative Medicine Market, 2020-2030
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2018 and 2019
3.3 Global Translational Regenerative Medicine: Market Forecast 2020-2030
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market - Changing Market Shares by Sector 2020-2030
3.3.3 Global Translational Regenerative Medicine Market - Current Developments in the Field, 2016, 2017 & 2018
4. Stem Cell Therapies: Leading Applications, 2020-2030
4.1 The Global Market for Stem Cell Therapies, 2018
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis - A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2020-2030
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2020-2030
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2020-2030
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2020-2030
4.8 Development Pipeline for Stem Cell Therapies, 2020-2030
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2018
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Adipocell (Bioheart)
4.8.1.8 Cx601 (TiGenix)
4.8.1.9 Adipose-Derived Stem Cells ( Plus Therapeutics)
4.8.1.10 Stempeucel (Stempeutics Research)
4.8.1.11 C-Cure (Cardio3 BioSciences)
4.8.1.12 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem) now Seneca Biopharma
4.8.5.4 MultiStem (Athersys)
4.8.5.5 ALD-401 (Cytomedix) now Nuo therapeutics
4.8.5.6 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration and License Agreement Between Pfizer And the London Project to Cure Blindness
4.9 ChondroCelect (TiGenix BV)
4.10 Stem Cells Therapy Market: Drivers and Restraints
5. Tissue Engineering Therapies: Leading Applications, 2020-2030
5.1 The Global Market for Tissue Engineered Therapies, 2018
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2020-2030
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2020-2030
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2020-2030
5.3.5 Epifix (MiMedx)
5.3.5.1 Epifix (MiMedx): Sales Forecast 2020-2030
5.3.6 Epicel (Vericel)
5.3.7 Grafix (Osiris Therapeutics)
5.3.8 MySkin and CyroSkin (Regenerys)
5.3.9 ReCell (Avita Medical)
5.3.9.1 ReCell (Avita Medical): Sales Forecast 2020-2030
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2020-2030
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints
6. Gene Therapies: Leading Applications, 2020-2030
6.1 The Global Market for Gene Therapies, 2018
6.2 Gene Therapies: Global Market Forecast 2020-2030
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2020-2030
6.3.4 IMLYGIC (talimogene laherparepvec) - (Amgen)
6.3.4.1 Clinical Trials and Development Efforts for IMLYGIC
6.3.4.2 Talimogene Laherparepvec (IMLYGIC) - Sales Forecast 2020-2030
6.5 Development Pipeline for Gene Therapies, 2020-2030
6.4.1 Late-Stage Pipeline Gene Therapies, 2020
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) - (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) - (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) - (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed at Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints
7. Leading National Markets 2020-2030
7.1 The Translational Regenerative Medicine Market by Region
7.2 Global Translational Regenerative Medicine Market: Regional Forecast 2020-2030
7.2.1 How Will Regional Market Shares Change to 2030?
8. North America Translational Regenerative Medicine Market 2020-2030
8.1. US Translational Regenerative Medicine Market: Market Forecast 2020-2030
8.1.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2020-2030
8.1.2 US Translational Regenerative Medicine Market: Market Forecast 2020-2030
8.1.3 The Regulatory Framework for Regenerative Medicine in the US
8.1.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
8.1.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
8.2. Canada Translational Regenerative Medicine Market: Trends and Developments
9. Europe Translational Regenerative Medicine Market 2020-2030
9.1 Europe: A Fragmented Regenerative Medicine Market
9.1.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2020-2030
9.1.2 European Regenerative Medicine Market: Market Forecast 2020-2030
9.2 Europe Markets: Changing Market Shares by Country, 2020-2030
9.2.1 Europe's Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
9.2.2 Regulation of Regenerative Medicine in the European Union
9.3 Germany
9.3.1 German Translational Regenerative Medicine Market: Market Forecast 2020-2030
9.4. France Translational Regenerative Medicine Market Forecast 2020-2030
9.5. U.K.
9.5.1. U.K. Translational Regenerative Medicine Market Forecast 2020-2030
9.5.2 Regulation of Stem Cell Research in the UK
9.6 Italy
9.6.1 Italy Translational Regenerative Medicine Market Forecast 2020-2030
9.7. Spain Translational Regenerative Medicine Market Forecast 2020-2030
9.8. Rest of Europe Translational Regenerative Medicine Market Forecast 2020-2030
9.8.1 Russia: Rising Interest in Regenerative Medicine Research
10. Asia-Pacific Translational Regenerative Medicine Market 2020-2030
10.1 Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
10.1.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2020-2030
10.1.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2020-2030
10.3 China: Encouraging Stem Cell R&D
10.3.1 Government Intervention into TRM Research in China
10.3.2 Regulation of Stem Cell Research in China
10.3.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
10.3.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
10.3.5 China Translational Regenerative Medicine Market Forecast 2020-2030
10.4. Japan: Difficulty in Translating Research into Commercialisation
10.4.1 Research Funding: A Major Determinant of Growth in Japan's Regenerative Medicine
10.4.2 Government Interventions in Promoting Stem Cell Research in Japan
10.4.3 Regulation of Regenerative Medicine in Japan
10.4.4 Accelerating Approvals of Regenerative Medicine Products in Japan
10.4.5 Japanese Translational Regenerative Medicine Market Forecast 2020-2030
10.5. India: An Emerging Market for Regenerative Medicine
10.5.1 Efforts in Stem Cell Research in India
10.5.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
10.5.3 India Translational Regenerative Medicine Market Forecast 2020-2030
10.6. Rest of Asia-Pacific Translational Regenerative Medicine Market: Trends and Developments
10.6.1 Australia: Encouraging Translational Regenerative Medicine
10.6.2 South Korea: First to Approve Stem Cell Treatments
10.6.3 A Regeneration in South Korea's Stem Cell Research Efforts
10.6.4. Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast 2020-2030
11. Latin America Translational Regenerative Medicine Market 2020-2030
11.1 Brazil
11.1.1 Brazil Translational Regenerative Medicine Market Forecast 2020-2030
11.1.1.1 Stem cell initiatives in Brazil
11.1.1.2 Stem cell regulation & strengths, weaknesses & opportunities in Brazil
11.2. Mexico Translational Regenerative Medicine Market: Trends and Developments
11.2.1 Stem cell initiatives in Mexico
11.2.2 Stem cell regulation & strengths, weaknesses & opportunities in Mexico
11.3. Rest of Latin America Translational Regenerative Medicine Market: Trends and Developments
12. Middle East & Africa Translational Regenerative Medicine Market 2020-2030
12.1. GCC Countries Translational Regenerative Medicine Market Forecast 2020-2030
12.2. South Africa Translational Regenerative Medicine Market Forecast 2020-2030
12.3. Rest of Middle East & Africa Translational Regenerative Medicine Market Forecast 2020-2030
13. Leading Companies in the Translational Regenerative Medicine Market
13.1 Introduction to the Leading Companies
13.2. Athersys, Inc.
13.2.1 Overview
13.2.2 Financial Overview
13.2.3 Athersys: Pipeline Analysis, 2018
13.2.3.1 MultiStem Technology - Potential Treatment for a Range of Diseases
13.2.4. Recent Transactions Summary
13.3. Avita Medical
13.3.1 Overview
13.3.2 Financial Overview
13.3.3 Avita Medical: Regenerative Medicine Portfolio, 2018
13.3.4 Avita Medical: Pipeline Analysis, 2018
13.3.5 Recent Transactions Summary
13.4. AxoGen, Inc.
13.4.1 Overview
13.4.2 Financial Overview
13.4.3 AxoGen, Inc.: Regenerative Medicine Portfolio, 2018
13.4.4 AxoGen, Inc.: Pipeline Analysis, 2018
13.4.5 Recent Transactions Summary
13.5. MEDIPOST Co., Ltd.
13.5.1 Overview
13.5.2 Financial Overview
13.5.3 MEDIPOST Co., Ltd.: Regenerative Medicine Portfolio, 2018
13.5.4 MEDIPOST Co., Ltd.: Pipeline Analysis, 2018
13.5.5 Recent Transactions Summary
13.6. NuVasive
13.6.1 Overview
13.6.2 Financial Overview
13.6.3 NuVasive: Regenerative Medicine Portfolio, 2018
13.6.4 NuVasive: Pipeline Analysis, 2018
13.6.5 Recent Transactions Summary
13.7. Astellas Pharma
13.7.1 Overview
13.7.2 Financial Overview
13.7.3 Astellas Pharma (Ocata Therapeutics): Pipeline Analysis, 2018
13.7.3.1 Retinal Pigment Epithelial Cell Therapy
13.7.3.2 Ocata's Other Therapeutic Platforms
13.7.4 Recent Transactions Summary
13.8. Organogenesis Holdings Inc.
13.8.1 Overview
13.8.2 Organogenesis Holdings Inc.: Regenerative Medicine Portfolio, 2018
13.8.3 Organogenesis Holdings Inc.: Pipeline Analysis, 2018
13.8.4 Recent Transactions Summary
13.9. Osiris Therapeutics, Inc.
13.9.1 Overview
13.9.2 Financial Overview
13.9.3 Osiris Therapeutics, Inc.: Regenerative Medicine Portfolio, 2018
13.9.4 Osiris Therapeutics, Inc.: Pipeline Analysis, 2018
13.9.5 Recent Transactions Summary
13.10. Pharmicell Co., Ltd.
13.10.1 Overview
13.10.2 Financial Overview
13.10.3 Pharmicell Co., Ltd.: Pipeline Analysis, 2018
13.11 Takeda Pharmaceutical Company Limited
13.11.1 Overview
13.11.2 Financial Overview
13.11.3 Takeda Pharmaceutical Company Limited (TiGenix): Pipeline Analysis, 2018
13.11.4 Recent Transactions Summary
13.12 uniQure N.V.
13.12.1 Overview
13.12.2 Financial Overview
13.12.3 UniQure N.V.: Pipeline Analysis, 2018
13.12.4 Recent Transactions Summary
13.13 Vericel Corporation
13.13.1 Overview
13.13.2 Financial Overview
13.13.3 Vericel Regenerative Medicine Portfolio, 2018
13.13.4 Vericel Corporation: Pipeline Analysis, 2018
13.13.4.1 The ixCELL-DCM Clinical Trial
13.13.5 Recent Transactions Summary
14. Qualitative Analysis of the Translational Regenerative Medicine Market
14.1 Market Factors Influencing the Translational Regenerative Medicine Market
14.2 SWOT Analysis of the Translational Regenerative Medicine Market
14.2.1 Strengths
14.2.1.1 Improvements in Regulatory Frameworks
14.2.1.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
14.2.1.3 Strong Support from Governments in Multiple Regions
14.2.1.4 Increasing Ease of Product Commercialisation and Market Access
14.2.2 Weaknesses
14.2.2.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
14.2.2.2. Lack of Funding from Venture Capital
14.2.2.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
14.2.2.4 Successful Commercialisation of TRM Products Requires New Business Models
14.2.3. Opportunities
14.2.3.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
14.2.3.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
14.2.3.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
14.3.4. Threats
14.3.4.1 Ethical Concerns Limiting R&D in Regenerative
14.3.4.2 Difficulty Establishing Evidence Base for Long-Term Efficacy of TRM Therapies
14.3.4.3 Rate of Scientific Progress - A Major Determinant of TRM Market Growth
14.3.4.4 Restraints on Reimbursement May Slow Growth
14.4 Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2020-2030
14.4.1 Threat of New Entrants
14.4.2 Threat of Substitutes
14.4.3 Power of Suppliers
14.4.4 Power of Buyers
14.4.5 Rivalry among Competitors
15. Research Interviews 2020
15.1 Alliance for Regenerative Medicine (ARM)
15.1.1 ARM
15.1.2 Growth in translational regenerative medicines
15.1.3 Regenerative medicine treatments
15.1.4 Challenges facing research and development
15.1.5 Regenerative Medicine Advanced Therapy Designation (RMAT)
15.1.6 Impact of 3-D printing on tissue engineering
15.1.7 The role of regulators
15.1.8 Future prospects
15.2 Mesoblast Ltd
15.2.1 Silviu Itescu, MBBS, FRACP ,Chief Executive Officer (Executive Director)
15.2.2 Stem cell therapy market
15.2.3 Limitations of current stem cell treatments
15.2.4 remestemcel-L
15.2.5 Mesoblast's core strategic imperatives
15.2.6 Development and enhancement of the remestemcel-L programme
15.2.7 Future prospects
15.3 SanBio
15.3.1 Company insight
15.3.2 Stem cell therapies in Asia/Pacific Market
15.3.3 Company strengths
15.3.4 Significance of RMAT designation for SB623 cell therapy
15.3.5 SB623 therapy
15.3.6 Partnerships and Collaborations
15.3.7 Future prospects
16. Conclusions
16.1 Overview of Current Market Conditions and Market Forecast, 2020-2030
16.2 Stem Cell Therapies Will Remain as the Dominant Submarket
16.3 Leading Regions in the Translational Regenerative Medicine Market in 2018
16.4 R&D Pipeline Products Crucial to Future Market Growth
16.5 What Does the Future Hold for Regenerative Medicine?
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2019
Table 2.2 Potency and Source of Stem Cells, 2019
Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2019
Table 2.4 Major Types of Stem Cells and Their Properties, 2019
Table 2.5 Terminology For Stem Cell Donor-Types, 2019
Table 2.6 Clinical Trial Phases, 2019
Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2018 and 2019
Table 3.2 The Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2030
Table 3.3 Global Translational Regenerative Medicine Market by Sector: CAGR (%), 2020-2025, 2025-2030, 2020-2030
Table 3.4 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2018, 2025 and 2030
Table 3.5 The Global Translational Regenerative Medicine Market: Current Developments in the Field, 2016, 2017 & 2018
Table 4.1 Stages of Osteogenesis
Table 4.2 Global Stem Cell Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 4.3 Osteocel Plus Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 4.4 Trinity ELITE Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 4.5 TEMCELL / Prochymal Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 4.6 Stem Cell Therapy Pipeline: Therapies in Development, Clinical Trials
Table 4.7 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials
Table 5.1 Selected Tissue Engineering Products Currently Available on the Market
Table 5.2 Global Tissue Engineering Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 5.3 Apligraf Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 5.4 Dermagraft Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 5.5 Epifix Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 5.6 ReCell Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 5.7 Tissue Engineering Pipeline: Therapies in Development, Clinical Trials
Table 5.8 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials
Table 6.1 Currently Available Gene Therapy Products
Table 6.2 Global Gene Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 6.3 Neovasculgen Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 6.4 Amgen: Gene Therapy Clinical Trials, 2018
Table 6.5 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2020-2030
Table 6.6 Gene Therapy Pipeline: Therapies in Development, Clinical Trials
Table 6.7 Gene Therapy Pipeline: Therapies in Development, Clinical Trials
Table 6.8 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2020
Table 6.9 Advantegene: Gene Therapy Clinical Trials
Table 6.10 Spark Therapeutics: Gene Therapy Clinical Trials
Table 6.11 Recent Developments in Gene Therapy for Use in Diabetes
Table 6.12 Gene Therapy Products in the Development Pipeline for Neurological Diseases
Table 7.1 Global Translational Regenerative Medicine Market by Region: Revenue ($m), 2018 and 2019
Table 7.2 Global Translational Regenerative Medicine Market Forecast by Region: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 7.3 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2020-2025, 2025-2030, 2020-2030
Table 7.4 Global Translational Regenerative Medicine Market by Region: Market Share (%), 2018, 2025, 2030
Table 8.1 North America Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018, 2025 and 2030
Table 8.2 North America Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 8.3 North America Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 8.4 US Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 8.5 Canada Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 9.1 Europe Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018, 2025 and 2030
Table 9.2 Europe Translational Regenerative Medicine Market by Country/Sub-region: Revenue ($m) and Market Share (%), 2018
Table 9.3 Europe Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 9.4 Europe Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 9.5 Europe Translational Regenerative Medicine Market by Country/Sub-region: CAGR (%), 2020-2025, 2025-2030, 2020-2030
Table 9.6 Germany Translational Regenerative Medicine Market Forecast, 2018-2030 ($m, AGR %, CAGR %)
Table 9.7 France Translational Regenerative Medicine Market Forecast, 2018-2030 ($m, AGR %, CAGR %)
Table 9.8 UK Translational Regenerative Medicine Market Forecast, 2018-2030 ($m, AGR %, CAGR %)
Table 9.9 Italy Translational Regenerative Medicine Market Forecast, 2018-2030 ($m, AGR %, CAGR %)
Table 9.10 Spain Translational Regenerative Medicine Market Forecast, 2018-2030 ($m, AGR %, CAGR %)
Table 9.11 Rest of Europe Translational Regenerative Medicine Market Forecast, 2018-2030 ($m, AGR %, CAGR %)
Table 10.1 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018, 2025 and 2030
Table 10.2 Asia-Pacific Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 10.3 Asia-Pacific Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 10.4 China Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2018-2030
Table 10.5 Japan Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2018-2030
Table 10.6 India Translational Regenerative Medicine Market Forecast: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
Table 10.7 Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 11.1 Latin America Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018, 2025 and 2030
Table 11.2 Latin America Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 11.3 Latin America Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 11.4 Brazil Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 11.5 Mexico Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 11.6 Rest of Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 12.1 Middle East & Africa Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018, 2025 and 2030
Table 12.2 Middle East & Africa Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 12.3 Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 12.4 GCC Countries Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 12.5 South Africa Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 12.6 Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 13.1. Athersys, Inc.: Overview, 2020
Table 13.2 Athersys, Inc.: Revenue ($m), AGR (%), 2014-2018
Table 13.3 Athersys: Regenerative Medicine Clinical Trials, 2018
Table 13.4 Avita Medical: Overview, 2019
Table 13.5 Avita Medical: Revenue ($m), AGR (%), 2014-2019
Table 13.6 Avita Medical: Regenerative Medicine Clinical Trials, 2018
Table 13.7. AxoGen, Inc.: Overview, 2019
Table 13.8 AxoGen, Inc.: Revenue ($m), AGR (%), 2013-2018
Table 13.9 AxoGen, Inc.: Regenerative Medicine Clinical Trials, 2018
Table 13.10. MEDIPOST Co., Ltd.: Overview, 2019
Table 13.11 MEDIPOST Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
Table 13.12 MEDIPOST Co., Ltd.: Regenerative Medicine Clinical Trials, 2018
Table 13.13. NuVasive.: Overview, 2019
Table 13.14 NuVasive: Revenue ($m), AGR (%), 2014-2018
Table 13.15 NuVasive: Regenerative Medicine Clinical Trials, 2018
Table 13.16. Astellas Pharma.: Overview, 2020
Table 13.17 Astellas Pharma: Revenue ($m), AGR (%), 2014-2018
Table 13.18 Astellas Pharma (Ocata Therapeutics): Regenerative Medicine Clinical Trials, 2018
Table 13.19. Organogenesis Holdings Inc.: Overview, 2019
Table 13.20 Organogenesis Holdings Inc.: Regenerative Medicine Clinical Trials
Table 13.21. Osiris Therapeutics, Inc.: Overview, 2019
Table 13.22 Osiris Therapeutics, Inc.: Revenue ($m), AGR (%), 2014-2018
Table 13.23 Osiris Therapeutics, Inc.: Regenerative Medicine Clinical Trials, 2018
Table 13.24. Pharmicell Co., Ltd.: Overview, 2019
Table 13.25 Pharmicell Co., Ltd.: Revenue ($m), AGR (%), 2014-2018
Table 13.28. Takeda Pharmaceutical Company Limited.: Overview, 2020
Table 13.29 Takeda Pharmaceutical Company Limited: Revenue ($m), AGR (%), 2014-2018
Table 13.30 Takeda Pharmaceutical Company Limited: Regenerative Medicine Clinical Trials, 2018
Table 13.31. UniQure N.V..: Overview, 2019
Table 13.32 UniQure N.V.: Revenue ($m), AGR (%), 2014-2018
Table 13.33 UniQure N.V.: Regenerative Medicine Clinical Trials, 2018
Table 13.34. Vericel Corporation.: Overview, 2020
Table 13.35 Vericel Corporation: Revenue ($m), AGR (%), 2014-2018
Table 13.36 Vericel Corporation: Regenerative Medicine Clinical Trials
Table 14.1 SWOT Analysis of the Global Translational Regenerative Medicine Market
Table 16.1 Global Translational Regenerative Medicine Market Forecast: Revenue ($m), and CAGR (%), 2018, 2025 and 2030
Table 16.2 Global Translational Regenerative Medicine Market by Sector: Revenue ($m) 2018, 2025, 2030
Table 16.3 Global Translational Regenerative Medicine Market by Region: Revenue ($m) 2018, 2025, 2030
Table 16.4 Global Translational Regenerative Medicine Market: Products in Late Stage Development, 2018
List of Figures
Figure 1.1 Global Translational Regenerative Medicine Market Segmentation Overview
Figure 2.1 Brief History of Stem Cell Research, 1900-2019
Figure 2.2 Examples of FDA-Approved Tissue Engineering Products
Figure 2.3 Brief History of Tissue Engineering, 1900-2019
Figure 2.4 Brief History of Gene Therapy, 1970-2019
Figure 3.1 The Global Translational Regenerative Medicine Market Forecast by Sector: Revenue ($m), 2018 and 2019
Figure 3.2 The Global Translational Regenerative Medicine Market Forecast: Revenue ($m), 2018 and 2019
Figure 3.3 Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), 2018-2030
Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2020-2025
Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2025-2030
Figure 3.6 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2020-2030
Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2019, 2025 and 2030
Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2019
Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2025
Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2030
Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 4.5 Stem Cell Therapies: Drivers and Restraints
Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 5.4 Epifix Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 5.5 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 5.6 Tissue Engineered Therapy: Drivers and Restraints
Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 6.3 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2020-2030
Figure 6.4 Gene Therapy: Drivers and Restraints
Figure 7.1 World Translational Regenerative Medicine Market: Revenues ($m) by Region, 2018
Figure 7.2 World Translational Regenerative Medicine Market: Revenues ($m) by Region, 2019
Figure 7.3 Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), 2018-2030
Figure 7.4 World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2018
Figure 7.5 World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2025
Figure 7.6 World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2030
Figure 8.1 North America Translational Regenerative Medicine Market Forecast: Revenues ($ m), AGR (%), 2018-2030
Figure 8.2 North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2018
Figure 8.3 North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2025
Figure 8.4 North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2030
Figure 8.5 North America Translational Regenerative Medicine: Drivers and Restraints
Figure 8.6 U.S. Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 8.7 Canada Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.1 Europe Translational Regenerative Medicine: Drivers and Restraints
Figure 9.2 Europe Translational Regenerative Medicine Market: Revenues ($m) by Country/Sub-region, 2018
Figure 9.3 Europe Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.4 Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2018
Figure 9.5 Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2025
Figure 9.6 Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2030
Figure 9.7 Germany Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2019-2030
Figure 9.8 France Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.9 U.K. Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.10 Italy Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.11 Spain Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.12 Rest of Europe Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.1 Asia-Pacific Translational Regenerative Medicine: Drivers and Restraints
Figure 10.2 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.3 Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2018
Figure 10.4 Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2025
Figure 10.5 Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2030
Figure 10.6 China Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.7 Japan Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.8 India Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.9 Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 11.1 Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 11.2 Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2018
Figure 11.3 Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2025
Figure 11.4 Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2030
Figure 11.5 Brazil Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 11.6 Mexico Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 11.7 Rest of Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 12.1 Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 12.2 Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2018
Figure 12.3 Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2025
Figure 12.4 Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2030
Figure 12.5 GCC Countries Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 12.6 South Africa Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 12.7 Rest of MEA Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 13.1 Athersys, Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 13.2 Athersys, Inc.: Business Segment Revenue Share (%), 2018
Figure 13.3 Avita Medical: Revenue ($m), AGR (%), 2014-2019
Figure 13.4 Avita Medical: Business Segment Revenue Share (%), 2019
Figure 13.5 AxoGen, Inc.: Revenue ($m), AGR (%), 2013-2018
Figure 13.6 MEDIPOST Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
Figure 13.7 MEDIPOST Co., Ltd.: Business Segment Revenue Share (%), 2017
Figure 13.8 NuVasive: Revenue ($m), AGR (%), 2014-2018
Figure 13.9 NuVasive: Business Segment Revenue Share (%), 2018
Figure 13.10 Astellas Pharma: Revenue ($m), AGR (%), 2014-2018
Figure 13.11 Astellas Pharma: Region Revenue Share (%), 2018
Figure 13.12 Osiris Therapeutics, Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 13.13 Osiris Therapeutics, Inc.: Product Revenue Share (%), 2018
Figure 13.14 Pharmicell Co., Ltd.: Revenue ($m), AGR (%), 2014-2018
Figure 13.15 Takeda Pharmaceutical Company Limited: Revenue ($m), AGR (%), 2014-2018
Figure 13.16 Takeda Pharmaceutical Company Limited: Regional Revenue Share (%), 2018
Figure 13.17 UniQure N.V.: Revenue ($m), AGR (%), 2014-2018
Figure 13.18 Vericel Corporation: Revenue ($m), AGR (%), 2014-2018
Figure 13.19 Vericel Corporation: Product Revenue Share (%), 2018
Figure 14.1 Porter's Five Force Analysis of the Translational Regenerative Medicine Market
Figure 16.1 Translational Regenerative Medicine Market Forecast by Sector: Revenue ($m), 2018-2030
Figure 16.2 Global Translational Regenerative Medicine Market Forecast: Revenue ($m) 2018, 2025, 2030
Figure 16.3 Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2019
Figure 16.4 Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2025
Figure 16.5 Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2030
Figure 16.6 The Global Translational Regenerative Medicine Market Forecast by Region: Revenue ($m), 2018, 2025, 2030
